SSIs – analysis of self-report data and economic impact

Czech version

Authors: L. Veverková ¹; P. Doležal ²; J. Habr ¹; M. Reška ¹; P. Vlček ¹; J. Konečný ¹; I. Čapov ¹; J. Žák ¹; I. Penka ¹
Authors‘ workplace: I. chirurgická klinika, LF MU a FN u sv. Anny v Brně ¹; Ekonomicko-správní, fakulta MU, Brno ²
Published in: Rozhl. Chir., 2025, roč. 104, č. 7, s. 289-294.
Category: Original articles
doi: https://doi.org/10.48095/ccrvch2025289

Overview

Background: Surgical site infections (SSIs) are a major health and economic problem. Increased morbidity, prolonged hospital stay and the need for additional treatments increase the financial costs of healthcare institutions. The aim of this article is to analyze the incidence of SSIs, their impact on hospital length of stay and economic burden under Czech conditions.

Methods: We analyzed hospitalizations in the period from 1^st January 2021 to 31^st December 2024 that were classified as SSI according to the CZ-DRG. A total of 2,134 hospitalizations were included, of which 212 (9.93%) were complicated by SSI. We recorded the length of hospital stay, number of reoperations and their duration.

Results: SSI hospitalizations accounted for 9.93% of all cases but 25.3% of hospital days. The economic impact of SSIs was expressed as a case-mix of 24.07%.

SSI cases required 19.66% of all operations and 16.43% of total operating time.

Conclusion: It is evident from the findings of this study that SSIs are not only a medical problem, but also an economic one. The economic analysis conducted in this study demonstrates that, even with higher reimbursement for SSI cases, this reimbursement does not cover the additional costs associated with prolonged hospitalization and the necessity for reoperations.

Keywords:

complications – surgical site infection – economic impact of SSI – surgical site infection prevention – cost

Sources

1. Centers for Disease Control and Prevention (CDC). 2023 National and State Healthcare-Associated Infections Progress Report [online]. Available from: https://arpsp.cdc.gov/profile/national-progress-2023/united-states.

2. Magill SS, O’Leary E, Janelle SJ et al. Changes in prevalence of health care- -associated infections in U.S. hospitals. N Engl J Med 2018; 379(18): 1732–1744. doi: 10.1056/NEJMoa1801550.

3. World Health Organization. Global guidelines for the prevention of surgical site infection. Geneva: World Health Organization 2016.

4. Allegranzi B, Zayed B, Bischoff P et al. New WHO recommendations on intraoperative and postoperative measures for surgical site infection prevention: an evidence-based global perspective. Lancet Infect Dis 2016; 16(12): e288–e303. doi: 10.1016/S1473-3099(16)30402-9.

5. Owens CD, Stoessel K. Surgical site infections: epidemiology, microbiology and prevention. J Hosp Infect 2008; 70(Suppl 2): 3–10. doi: 10.1016/S0195-6701(08)60017-1.

6. Anderson DJ, Podgorny K, Berríos- -Torres SI et al. Strategies to prevent surgical site infections in acute care hospitals: 2014 update. Infect Control Hosp Epidemiol 2014; 35(6): 605–627. doi: 10.1086/676022.

7. de Lissovoy G, Fraeman K, Hutchins V et al. Surgical site infection: incidence and impact on hospital utilization and treatment costs. Am J Infect Control 2009; 37(5): 387–397. doi: 10.1016/ j.ajic.2008.12.010.

8. Badia JM, Casey AL, Petrosillo N et al. Impact of surgical site infection on healthcare costs and patient outcomes: a systematic review in six European countries. J Hosp Infect 2017; 96(1): 1–15. doi: 10.1016/ j.jhin.2017.03.004.

9. Jenks PJ, Laurent M, McQuarry S et al. Clinical and economic burden of surgical site infection (SSI) and predicted financial consequences of elimination of SSI from an English hospital. J Hosp Infect 2014; 86(1): 24–33. doi: 10.1016/ j.jhin.2013.09.012.

10. Leaper DJ, Edmiston CE. World Health Organization: global guidelines for the prevention of surgical site infection. J Hosp Infect 2017; 95(2): 135–136. doi: 10.1016/j.jhin.2016.12.016.

11. Merkow RP, Ju MH, Chung JW et al. Underlying reasons associated with hospital readmission following surgery in the United States. JAMA 2015; 313(5): 483–495. doi: 10.1001/jama.2014.18614.

12. Urban JA. Cost analysis of surgical site infections. Surg Infect (Larchmt) 2006; 7(Suppl 1): S19–S22. doi: 10.1089/sur.2006.7.s1-19.

13. Ulrych J, Adámková V, Gürlich R et al. Současná diagnostika a léčba chirurgických infekcí kůže a mekkých tkání. Rozhl Chir 2022; 101(7): 300–311. doi: 10.33699/PIS.2022.101.7.300-311.

14. Centers for Disease Control and Prevention (CDC). Surgical Site Infection (SSI) Event. 2016 [online]. Available from: http://www.cdc.gov/nhsn/acute-care-hospital/ssi/.

15. Stryja J, Repko M, Hájek M et al. Doporučené postupy – Infekce v místě chirurgického výkonu – prevence a léčba. Adaptovaný doporučený postup – World Health Organization. Global guidelines on the prevention of surgical site infection 2018 [online]. Available from: https://kdp.uzis.cz/res/guideline/32-ssi-infekce-v-miste-chirurgickeho-vykonu-final.pdf.

doc. MUDr. Lenka Veverková, Ph.D.

Lékařská fakulta MU

Kamenice 753/5

625 00 Brno

lvever@med.muni.cz

ORCID autorů

L. Veverková 0000-0001-6578-9274

P. Vlček 0000-0002-7344-9752

J. Konečný 0009-0005-5617-4389

I. Penka 0009-0008-4766-2411